Total Payments
$548,767
2024 Payments
$99,857
Companies
48
Transactions
943
Medicare Patients
19,568
Medicare Billing
$2.4M
Payment Breakdown by Category
Other$352,325 (64.2%)
Research$92,800 (16.9%)
Travel$75,770 (13.8%)
Food & Beverage$25,792 (4.7%)
Consulting$1,900 (0.3%)
Education$180.10 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $352,325 | 115 | 64.2% |
| Unspecified | $92,800 | 2 | 16.9% |
| Travel and Lodging | $75,770 | 142 | 13.8% |
| Food and Beverage | $25,792 | 676 | 4.7% |
| Consulting Fee | $1,900 | 3 | 0.3% |
| Education | $180.10 | 5 | 0.0% |
Payments by Type
General
$455,967
941 transactions
Research
$92,800
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $426,396 | 481 | $0 (2024) |
| Eli Lilly and Company | $92,800 | 2 | $0 (2024) |
| Medtronic Vascular, Inc. | $12,071 | 81 | $0 (2020) |
| Abbott Laboratories | $2,210 | 58 | $0 (2024) |
| Boston Scientific Corporation | $1,834 | 13 | $0 (2024) |
| BIOTRONIK INC. | $1,728 | 8 | $0 (2021) |
| Esperion Therapeutics, Inc. | $1,694 | 5 | $0 (2022) |
| ABIOMED | $1,582 | 23 | $0 (2024) |
| Amgen Inc. | $937.16 | 46 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $745.62 | 43 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $99,857 | 57 | Eli Lilly and Company ($92,800) |
| 2023 | $13,790 | 91 | Janssen Pharmaceuticals, Inc ($10,926) |
| 2022 | $53,686 | 128 | Janssen Pharmaceuticals, Inc ($51,277) |
| 2021 | $15,219 | 87 | Janssen Pharmaceuticals, Inc ($12,095) |
| 2020 | $9,821 | 113 | Janssen Pharmaceuticals, Inc ($5,602) |
| 2019 | $117,583 | 176 | Janssen Pharmaceuticals, Inc ($114,102) |
| 2018 | $118,829 | 130 | Janssen Pharmaceuticals, Inc ($111,064) |
| 2017 | $119,982 | 161 | Janssen Pharmaceuticals, Inc ($115,540) |
All Payment Transactions
943 individual payment records from CMS Open Payments — Page 1 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/11/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $14.39 | General |
| Category: Cardiovascular | ||||||
| 10/28/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/09/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/03/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $18.89 | General |
| Category: Cardiovascular | ||||||
| 09/30/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $24.10 | General |
| Category: Coronary | ||||||
| 09/16/2024 | Boston Scientific Corporation | AVVIGO Guidance System (Device) | Food and Beverage | In-kind items and services | $146.12 | General |
| Category: AVVIGO_IC | ||||||
| 09/16/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $56.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/11/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/10/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $29,502.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 09/09/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $22.83 | General |
| Category: Heart Failure and Hypertension | ||||||
| 09/04/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/03/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $63,297.60 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 09/03/2024 | Abbott Laboratories | CONFIRM RX (Device) | Food and Beverage | In-kind items and services | $17.16 | General |
| Category: Cardiac Rhythm Management | ||||||
| 08/28/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $21.93 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/14/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $127.04 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/06/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $48.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/05/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $17.51 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/24/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.68 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/19/2024 | Abbott Laboratories | CONFIRM RX (Device) | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: Cardiac Rhythm Management | ||||||
| 07/10/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.23 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/03/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: DIABETES | ||||||
| 06/25/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $127.64 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 06/24/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 06/13/2024 | Abbott Laboratories | PERCLOSE PROSTYLE (Device) | Food and Beverage | In-kind items and services | $2.02 | General |
| Category: Vascular | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $63,298 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $29,502 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 36 | 6,051 | 17,988 | $2.5M | $872,541 |
| 2022 | 38 | 5,260 | 12,101 | $1.8M | $613,753 |
| 2021 | 33 | 4,039 | 7,194 | $1.4M | $481,324 |
| 2020 | 36 | 4,218 | 7,639 | $1.5M | $459,250 |
Total Patients
19,568
Total Services
44,922
Medicare Billing
$2.4M
Procedure Codes
143
All Medicare Procedures & Services
143 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 739 | 1,799 | $395,899 | $151,439 | 38.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 365 | 375 | $432,240 | $115,512 | 26.7% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 385 | 3,175 | $219,295 | $107,949 | 49.2% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 360 | 3,422 | $197,856 | $95,893 | 48.5% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 326 | 2,247 | $177,884 | $74,148 | 41.7% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 367 | 744 | $215,498 | $66,494 | 30.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 487 | 499 | $253,910 | $64,861 | 25.5% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 212 | 1,018 | $89,290 | $39,564 | 44.3% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 197 | 785 | $67,476 | $28,969 | 42.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 136 | 151 | $44,145 | $19,360 | 43.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 163 | 163 | $56,044 | $17,596 | 31.4% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 370 | 378 | $54,830 | $16,968 | 30.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 218 | 253 | $38,442 | $14,861 | 38.7% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 79 | 80 | $76,666 | $14,522 | 18.9% |
| 92928 | Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | Facility | 2023 | 18 | 21 | $25,728 | $8,281 | 32.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 460 | 606 | $26,274 | $5,923 | 22.5% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 28 | 132 | $16,104 | $4,597 | 28.5% |
| 93459 | Insertion of tube in left lower heart chamber, coronary artery and bypass graft for diagnosis with review by radiologist | Facility | 2023 | 12 | 12 | $9,148 | $2,839 | 31.0% |
| J1245 | Injection, dipyridamole, per 10 mg | Office | 2023 | 169 | 883 | $6,181 | $2,598 | 42.0% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 113 | 130 | $8,412 | $2,440 | 29.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 214 | 218 | $5,886 | $2,251 | 38.2% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 41 | 98 | $7,064 | $2,131 | 30.2% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 53 | 126 | $7,563 | $1,914 | 25.3% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 17 | 74 | $4,305 | $1,432 | 33.3% |
| 93308 | Ultrasound of heart, follow-up | Office | 2023 | 18 | 23 | $5,057 | $1,387 | 27.4% |
About Dr. Joseph Weinstein, MD
Dr. Joseph Weinstein, MD is a Interventional Cardiology healthcare provider based in Memphis, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1922003037.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Weinstein, MD has received a total of $548,767 in payments from pharmaceutical and medical device companies, with $99,857 received in 2024. These payments were reported across 943 transactions from 48 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($352,325).
As a Medicare-enrolled provider, Weinstein has provided services to 19,568 Medicare beneficiaries, totaling 44,922 services with total Medicare billing of $2.4M. Data is available for 4 years (2020–2023), covering 143 distinct procedure/service records.
Ad
Practice Information
- Specialty Interventional Cardiology
- Other Specialties Interventional Cardiology, Interventional Cardiology
- Location Memphis, TN
- Active Since 06/15/2005
- Last Updated 02/07/2024
- Taxonomy Code 207RI0011X
- Entity Type Individual
- NPI Number 1922003037
Products in Payments
- XARELTO (Drug) $426,492
- Resolute (Device) $9,795
- NEXLIZET (Drug) $1,620
- Impella (Device) $1,582
- VenaSeal (Device) $1,431
- GENERAL - VASCULAR ACCESS (Device) $1,033
- Repatha (Biological) $801.61
- ENTRESTO (Drug) $543.54
- LifeVest (Device) $475.44
- HawkOne (Device) $399.87
- Indigo System (Device) $384.10
- BRILINTA (Drug) $358.40
- JARDIANCE (Drug) $345.87
- Assurity Pacemaker (Device) $341.35
- ClosureFast (Device) $330.86
- Carnation Ambulatory Monitor (Device) $310.00
- ELIQUIS (Drug) $300.88
- CRT-Ds (Device) $284.39
- VERQUVO (Drug) $270.30
- TELEPATCH CARDIAC MONITOR (Device) $223.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Interventional Cardiology Doctors in Memphis
Dr. Indranill Basu Ray, Md, MD
Interventional Cardiology — Payments: $82,562
Interventional Cardiology $82,562
Dr. Sushant Khaire, M.d, M.D
Interventional Cardiology — Payments: $10,269
Interventional Cardiology $10,269
David Wolford, Md, MD
Interventional Cardiology — Payments: $7,968
Interventional Cardiology $7,968
Dr. Oluwaseun Akinseye, M.d, M.D
Interventional Cardiology — Payments: $7,141
Interventional Cardiology $7,141
Mannu Nayyar, M.d, M.D
Interventional Cardiology — Payments: $5,579
Interventional Cardiology $5,579
Raj Dave, Md, MD
Interventional Cardiology — Payments: $4,232
Interventional Cardiology $4,232